OpGen, Inc. (OPGN) Has Another Very Strong Trading Session

OpGen, Inc. (NASDAQ:OPGN) Logo

The stock of OpGen, Inc. (NASDAQ:OPGN) is a huge mover today! The stock increased 21.39% or $1.41 during the last trading session, reaching $8. About 592,594 shares traded or 125.26% up from the average. OpGen, Inc. (NASDAQ:OPGN) has declined 81.47% since September 13, 2018 and is downtrending. It has underperformed by 81.47% the S&P500.
The move comes after 9 months positive chart setup for the $7.06M company. It was reported on Sep, 13 by Barchart.com. We have $8.72 PT which if reached, will make NASDAQ:OPGN worth $635,220 more.

Analysts await OpGen, Inc. (NASDAQ:OPGN) to report earnings on November, 12. They expect $-2.60 earnings per share, up 75.47 % or $8.00 from last year’s $-10.6 per share. After $-3.00 actual earnings per share reported by OpGen, Inc. for the previous quarter, Wall Street now forecasts -13.33 % EPS growth.

More notable recent OpGen, Inc. (NASDAQ:OPGN) news were published by: Benzinga.com which released: “Mid-Morning Market Update: Markets Open Higher; Navistar Tops Q3 Estimates – Benzinga” on September 04, 2019, also Globenewswire.com with their article: “OpGen Receives Regulatory Approval to Market Pathogen Identification Products in Colombia – GlobeNewswire” published on December 04, 2018, Globenewswire.com published: “OpGen Announces Date of First Quarter 2019 Financial Results Conference Call – GlobeNewswire” on May 07, 2019. More interesting news about OpGen, Inc. (NASDAQ:OPGN) were released by: Seekingalpha.com and their article: “SDRL, GEVO among premarket gainers – Seeking Alpha” published on September 04, 2019 as well as Seekingalpha.com‘s news article titled: “OpGen files for $6.5M stock offering – Seeking Alpha” with publication date: March 02, 2019.

OpGen, Inc., a precision medicine company, engages in developing molecular information services and products to combat infectious diseases in the healthcare industry worldwide. The company has market cap of $7.06 million. The firm utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It currently has negative earnings. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

OpGen, Inc. (NASDAQ:OPGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.